Login to Your Account


2015 American Society of Clinical Oncology

CHICAGO – Bristol-Myers Squibb Co.'s Opdivo (nivolumab), approved in March to treat certain patients with squamous NSCLC, can also provide significant benefit to patients with the more common nonsquamous form of NSCLC. more »